← Back to Clinical Trials
Recruiting Phase 2 NCT07108283

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Nonsegmental Vitiligo
Sponsor Takeda
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-11-03
Completion 2027-10-12
Interventions
ZasocitinibPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.

Eligibility Criteria

Inclusion criteria: Participant willingness: 1. Participant is willing and able to understand and fully comply with trial procedures and requirements (including digital tools and applications), in the opinion of the investigator. 2. Participant has provided written informed consent and any required privacy authorization before the initiation of any trial procedures. Disease Characteristics: 3. Participants must have a clinical diagnosis of nonsegmental vitiligo: F-VASI greater than or equal to (\>=) 0.5 and a T-VASI \>= 5 and less than or equal to (\<=) 50 at screening and Day 1. Age and Reproductive Status: 4. Participant is aged \>=18 years to \<=75 years old at the time of consent. 5. Participant meets the following birth control requirement: An individual with potential for pregnancy who is now of nonchildbearing potential with laboratory confirmation of postmenopausal status; or an individual with potential for pregnancy who if sexually active with a nonsterilized individual who p

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}